StockData

BGM Group Ltd. (BGM) stock

BGMNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 20-F on Jul 21, 2026Score 9/30
$8.13+0.12 (+1.50%)

Close on Nov 17, 2026Market cap $3.26BP/E –Yield –

BGM r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $672.67K, down 50.6% from the year before. The highest annual figure on record is $1.36M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Sep 30, 2025$672.67K-50.6%
FY2024Sep 30, 2024$1.36M+139.5%
FY2023Sep 30, 2023$568.47K-53.6%
FY2022Sep 30, 2022$1.22M+15204.3%
FY2021Sep 30, 2021$8.00K-85.2%
FY2020Sep 30, 2020$54.00K+22.7%
FY2019Sep 30, 2019$44.00K–

More BGM figures

See a number that looks wrong?